JP6404838B2 - ブロモドメイン阻害剤として有用なカルバゾール化合物 - Google Patents
ブロモドメイン阻害剤として有用なカルバゾール化合物 Download PDFInfo
- Publication number
- JP6404838B2 JP6404838B2 JP2015560300A JP2015560300A JP6404838B2 JP 6404838 B2 JP6404838 B2 JP 6404838B2 JP 2015560300 A JP2015560300 A JP 2015560300A JP 2015560300 A JP2015560300 A JP 2015560300A JP 6404838 B2 JP6404838 B2 JP 6404838B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- dimethyl
- carbazole
- isoxazolyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LDKXJCWVRHZKNW-IGKLALHGSA-N CC(/C(/c(cc1C(OC)=O)ccc1Nc1cc(S(C)(=O)=O)ccc1)=C(/C)\O)=N Chemical compound CC(/C(/c(cc1C(OC)=O)ccc1Nc1cc(S(C)(=O)=O)ccc1)=C(/C)\O)=N LDKXJCWVRHZKNW-IGKLALHGSA-N 0.000 description 1
- QCUFCWDFWNLYCL-UHFFFAOYSA-N CC(C)(C)OC(Nc1ccc(c2cc(Br)cc(C(N)=O)c2[n]2CC3CC3)c2c1)=O Chemical compound CC(C)(C)OC(Nc1ccc(c2cc(Br)cc(C(N)=O)c2[n]2CC3CC3)c2c1)=O QCUFCWDFWNLYCL-UHFFFAOYSA-N 0.000 description 1
- VTVJKNNVMMDIGB-UHFFFAOYSA-N CC(Nc1ccc(c(cc(cc2C(N)=O)-c3c(C)[o]nc3C)c2[n]2CC3CC3)c2c1)=O Chemical compound CC(Nc1ccc(c(cc(cc2C(N)=O)-c3c(C)[o]nc3C)c2[n]2CC3CC3)c2c1)=O VTVJKNNVMMDIGB-UHFFFAOYSA-N 0.000 description 1
- 0 CC1C(c(cc2C(N)=O)cc3c2[n](CC2CC2)c2cc(N(CCC4)S4(=O)=O)ccc32)=C(C)O*1 Chemical compound CC1C(c(cc2C(N)=O)cc3c2[n](CC2CC2)c2cc(N(CCC4)S4(=O)=O)ccc32)=C(C)O*1 0.000 description 1
- MLYVFSWSGBNTSC-UHFFFAOYSA-N CC[n](c1c2)c(c(C(N)=S)cc(-c3c(C)[o]nc3C)c3)c3c1ccc2C(N1CCOCC1)=O Chemical compound CC[n](c1c2)c(c(C(N)=S)cc(-c3c(C)[o]nc3C)c3)c3c1ccc2C(N1CCOCC1)=O MLYVFSWSGBNTSC-UHFFFAOYSA-N 0.000 description 1
- PCBHQVZHXSODCL-TXEJJXNPSA-N C[C@H](C1)O[C@@H](C)CN1C(c(cc1)cc2c1c(c(F)c(cc1C(N)=O)-c3c(C)[o]nc3C)c1[nH]2)=O Chemical compound C[C@H](C1)O[C@@H](C)CN1C(c(cc1)cc2c1c(c(F)c(cc1C(N)=O)-c3c(C)[o]nc3C)c1[nH]2)=O PCBHQVZHXSODCL-TXEJJXNPSA-N 0.000 description 1
- ZTQQZCJPOWEODU-CALCHBBNSA-N C[C@H](C1)O[C@@H](C)CN1C(c(cc1)cc2c1c1cc(-c3c(C)[o]nc3C)cc(-c3nnc[nH]3)c1[n]2CC1CC1)=O Chemical compound C[C@H](C1)O[C@@H](C)CN1C(c(cc1)cc2c1c1cc(-c3c(C)[o]nc3C)cc(-c3nnc[nH]3)c1[n]2CC1CC1)=O ZTQQZCJPOWEODU-CALCHBBNSA-N 0.000 description 1
- WHRLCCIKKJLYIS-UHFFFAOYSA-N Cc1c[s]c(-c2cc(-c3c(C)[o]nc3C)cc3c2[nH]c2c3ccc(C(N3CCOCC3)=S)c2)n1 Chemical compound Cc1c[s]c(-c2cc(-c3c(C)[o]nc3C)cc3c2[nH]c2c3ccc(C(N3CCOCC3)=S)c2)n1 WHRLCCIKKJLYIS-UHFFFAOYSA-N 0.000 description 1
- XDLVEXWCOUZJEJ-UHFFFAOYSA-N Cc1n[o]c(C)c1-c(cc12)cc(C(N)=O)c1[n](CC1CC1)c1c2c(S(C)(=O)=O)ccc1 Chemical compound Cc1n[o]c(C)c1-c(cc12)cc(C(N)=O)c1[n](CC1CC1)c1c2c(S(C)(=O)=O)ccc1 XDLVEXWCOUZJEJ-UHFFFAOYSA-N 0.000 description 1
- NHWHSMDTTBHBKT-UHFFFAOYSA-N Cc1n[o]c(C)c1-c(cc1C(N)=O)cc(c2cc(OC)ccc22)c1[n]2S(C)(=O)=O Chemical compound Cc1n[o]c(C)c1-c(cc1C(N)=O)cc(c2cc(OC)ccc22)c1[n]2S(C)(=O)=O NHWHSMDTTBHBKT-UHFFFAOYSA-N 0.000 description 1
- FIOXQCPFKCJCJV-UHFFFAOYSA-N Cc1n[o]c(C)c1-c(cc1C(N)=O)cc2c1[n](CC1CC1)c1cc(C(O)=O)ccc21 Chemical compound Cc1n[o]c(C)c1-c(cc1C(N)=O)cc2c1[n](CC1CC1)c1cc(C(O)=O)ccc21 FIOXQCPFKCJCJV-UHFFFAOYSA-N 0.000 description 1
- CILBIBYKWQONQP-UHFFFAOYSA-N Cc1n[o]c(C)c1-c(cc1C(N)=O)cc2c1[n](CC1CC1)c1cc(N(CCO3)C3=O)ccc21 Chemical compound Cc1n[o]c(C)c1-c(cc1C(N)=O)cc2c1[n](CC1CC1)c1cc(N(CCO3)C3=O)ccc21 CILBIBYKWQONQP-UHFFFAOYSA-N 0.000 description 1
- QQEAUQQMRLDTHJ-UHFFFAOYSA-N Cc1n[o]c(C)c1-c(cc1C(N)=O)cc2c1[n](CC1CC1)c1cc(NC(OC)=O)ccc21 Chemical compound Cc1n[o]c(C)c1-c(cc1C(N)=O)cc2c1[n](CC1CC1)c1cc(NC(OC)=O)ccc21 QQEAUQQMRLDTHJ-UHFFFAOYSA-N 0.000 description 1
- VHLPCLUUUJLWKU-UHFFFAOYSA-N NC(c1cc(Br)cc2c1[n](CC1CC1)c1cc(C(O)=O)ccc21)=O Chemical compound NC(c1cc(Br)cc2c1[n](CC1CC1)c1cc(C(O)=O)ccc21)=O VHLPCLUUUJLWKU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770021P | 2013-02-27 | 2013-02-27 | |
| US61/770,021 | 2013-02-27 | ||
| PCT/US2014/018914 WO2014134267A1 (en) | 2013-02-27 | 2014-02-27 | Carbazole compounds useful as bromodomain inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513137A JP2016513137A (ja) | 2016-05-12 |
| JP2016513137A5 JP2016513137A5 (OSRAM) | 2017-03-30 |
| JP6404838B2 true JP6404838B2 (ja) | 2018-10-17 |
Family
ID=50272771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560300A Active JP6404838B2 (ja) | 2013-02-27 | 2014-02-27 | ブロモドメイン阻害剤として有用なカルバゾール化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10053454B2 (OSRAM) |
| EP (1) | EP2961747B1 (OSRAM) |
| JP (1) | JP6404838B2 (OSRAM) |
| CN (1) | CN105189488B (OSRAM) |
| WO (1) | WO2014134267A1 (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2014164596A1 (en) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| CN105492439B (zh) | 2013-06-21 | 2019-11-22 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的取代的双环化合物 |
| AR096837A1 (es) | 2013-07-08 | 2016-02-03 | Incyte Corp | Heterociclos tricíclicos como inhibidores de proteínas bet |
| WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| PL3466949T3 (pl) * | 2013-12-24 | 2021-05-31 | Bristol-Myers Squibb Company | Związek tricykliczny jako środki przeciwrakowe |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| UA119870C2 (uk) | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
| US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| HK1246273B (en) | 2014-12-01 | 2019-12-06 | 恒翼生物医药(上海)股份有限公司 | Substituted pyridines as bromodomain inhibitors |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| WO2016183114A1 (en) * | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| WO2016183115A1 (en) * | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| IL263824B2 (en) | 2016-06-20 | 2023-10-01 | Incyte Corp | Crystals in solid form in the presence of an inhibitor |
| KR102625861B1 (ko) * | 2016-06-28 | 2024-01-17 | 삼성디스플레이 주식회사 | 헤테로시클릭 화합물 및 이를 포함한 유기 발광 소자 |
| WO2020092638A1 (en) | 2018-10-30 | 2020-05-07 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
| CN110003204B (zh) * | 2019-04-30 | 2020-08-11 | 上海勋和医药科技有限公司 | 一种bet蛋白抑制剂、其制备方法及用途 |
| CN114286818B (zh) | 2019-07-02 | 2024-09-20 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US12016847B2 (en) | 2021-03-12 | 2024-06-25 | Bristol-Myers Squibb Company | Methods of treating prostate cancer |
| IL320298A (en) * | 2022-10-15 | 2025-06-01 | Pillai Universal Llc | New therapeutic molecule |
| CN118993985A (zh) * | 2023-05-17 | 2024-11-22 | 中国医学科学院药物研究所 | 一种具有抗肿瘤活性的化合物，其制备方法及制药用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS545433A (en) * | 1977-06-14 | 1979-01-16 | Ricoh Co Ltd | Photoreceptor for electrophotography |
| JPH0812430B2 (ja) * | 1986-07-07 | 1996-02-07 | キヤノン株式会社 | 電子写真感光体 |
| US6602619B2 (en) * | 2001-10-19 | 2003-08-05 | Lightronik Technology Inc. | Organic EL device |
| US7955716B2 (en) * | 2003-06-09 | 2011-06-07 | Hitachi Chemical Co., Ltd. | Metal coordination compound, polymer composition, and organic electroluminescent device employing same |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| US8815840B2 (en) * | 2008-12-19 | 2014-08-26 | Bristol-Myers Squibb Company | Carbazole and carboline kinase inhibitors |
| JP5623996B2 (ja) | 2010-09-21 | 2014-11-12 | 株式会社半導体エネルギー研究所 | カルバゾール誘導体 |
| CN102167913B (zh) * | 2011-02-25 | 2013-09-25 | 中国科学院上海有机化学研究所 | 含多联咔唑的有机染料及其制备方法和应用 |
| JP5842630B2 (ja) | 2011-03-16 | 2016-01-13 | 株式会社リコー | カルバゾール誘導体、及び半導体ナノ結晶 |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| PL3466949T3 (pl) | 2013-12-24 | 2021-05-31 | Bristol-Myers Squibb Company | Związek tricykliczny jako środki przeciwrakowe |
-
2014
- 2014-02-27 WO PCT/US2014/018914 patent/WO2014134267A1/en not_active Ceased
- 2014-02-27 EP EP14709856.0A patent/EP2961747B1/en active Active
- 2014-02-27 JP JP2015560300A patent/JP6404838B2/ja active Active
- 2014-02-27 CN CN201480023597.XA patent/CN105189488B/zh active Active
- 2014-02-27 US US14/770,230 patent/US10053454B2/en active Active
-
2017
- 2017-02-13 US US15/430,883 patent/US10196387B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105189488B (zh) | 2018-07-24 |
| US10053454B2 (en) | 2018-08-21 |
| EP2961747B1 (en) | 2017-11-15 |
| US20170152248A1 (en) | 2017-06-01 |
| JP2016513137A (ja) | 2016-05-12 |
| US20160009701A1 (en) | 2016-01-14 |
| CN105189488A (zh) | 2015-12-23 |
| US10196387B2 (en) | 2019-02-05 |
| EP2961747A1 (en) | 2016-01-06 |
| WO2014134267A1 (en) | 2014-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6404838B2 (ja) | ブロモドメイン阻害剤として有用なカルバゾール化合物 | |
| JP6395731B2 (ja) | ブロモドメイン阻害剤として有用なカルバゾール化合物 | |
| RU2743074C2 (ru) | Соединения, активные по отношению к бромодоменам | |
| US10112941B2 (en) | Tricyclic compounds as anticancer agents | |
| KR102457145B1 (ko) | 항암제로서의 트리시클릭 화합물 | |
| US9637518B2 (en) | IAP antagonists | |
| US9738630B2 (en) | Inhibitors of lysine methyl transferase | |
| US9725449B2 (en) | Tricyclic compounds as anticancer agents | |
| US20140135270A1 (en) | Macrocyclic compounds for inhibition of inhibitors of apoptosis | |
| US10683290B2 (en) | Tricyclic compounds as anticancer agents | |
| US9605022B2 (en) | Macrocyclic compounds for inhibition of inhibitors of apoptosis | |
| TW201444828A (zh) | 可作爲溴區結構域蛋白抑制劑之咔唑化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170224 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170224 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180130 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180516 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180821 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180913 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6404838 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |